Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548860 · ClinicalTrials.gov registry record · Phase 3
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
A Phase 3 study of Anemia, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,018
- Enrollment target
- 1
- Study location
NCT00548860 is a Phase 3 study of Anemia that has completed, run by American Regent. The registered enrollment target is 2,018 participants, above the 400-participant average among 72 other Anemia trials with a reported enrollment target (405% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00548860, a Phase 3 study of Anemia, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,018 participants
- Enrollment target
- 1
- Study location
Study Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
Conditions Studied
Interventions
- DRUG Ferric Carboxymaltose
- DRUG Standard Medical Care (SMC)
Study Locations (1)
Pennsylvania
- Luitpold Pharmaceuticals - Norristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,018 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548860
The ClinicalTrials.gov registry entry for NCT00548860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,018 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 400-participant average among 72 other Anemia trials with a reported enrollment target (405% higher). The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Ferric Carboxymaltose is the first listed.
NCT00548860 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00548860 about?
NCT00548860 is a clinical study titled "Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients". The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
What is the current status of trial NCT00548860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,018 participants. The study started on 2007-10. Estimated completion is 2009-07.
What conditions does trial NCT00548860 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00548860?
The interventions under investigation include: Ferric Carboxymaltose (DRUG), Standard Medical Care (SMC) (DRUG).
Who is sponsoring clinical trial NCT00548860?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00548860 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.